1
Clinical Trials associated with Melanoma vaccine(C.H. Boehringer Sohn AG & Co. KG)An Open-label, Multicenter, Controlled, Combined Parallel Group and Dose Escalation (0, 0.12, 1.2, 12.0 µg IL-2/10**8 Cells/24 Hours) Study, to Evaluate the Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 Containing Melanoma Cells Transfected With the Human IL-2 Gene in Patients With Advanced Malignant Melanoma
Evaluation of safety and tolerability of four intradermal injections given at two week intervals. In addition the efficacy of transferrinfection was determined by quantifying Interleukin 2 (IL-2), which was locally produced by the implanted, transfected allogenic melanoma cells at the injection sites. Further determination of tumor specific and clinical host responses induced or augmented by the treatment were determined.
100 Clinical Results associated with Melanoma vaccine(C.H. Boehringer Sohn AG & Co. KG)
100 Translational Medicine associated with Melanoma vaccine(C.H. Boehringer Sohn AG & Co. KG)
100 Patents (Medical) associated with Melanoma vaccine(C.H. Boehringer Sohn AG & Co. KG)
100 Deals associated with Melanoma vaccine(C.H. Boehringer Sohn AG & Co. KG)